Maa: Irlanti
Kieli: englanti
Lähde: HPRA (Health Products Regulatory Authority)
CYTARABINE
Fannin Limited
L01BC01
CYTARABINE
50 Mg/Ml
Solution for Inj/Inf
Product subject to prescription which may not be renewed (A)
Pyrimidine analogues
Authorised
2012-12-07
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT CYTARABINE “EBEWE” 20MG/ML SOLUTION FOR INJECTION OR INFUSION CYTARABINE “EBEWE” 50MG/ML SOLUTION FOR INJECTION OR INFUSION CYTARABINE “EBEWE” 100MG/ML SOLUTION FOR INJECTION OR INFUSION READ THIS ENTIRE LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have further questions, please ask your doctor or your nurse. - If you get any side effects, talk to your doctor or nurse, this includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1. What Cytarabine “Ebewe” is and what it is used for 2. What you need to know before you take Cytarabine Ebewe” 3. How to take Cytarabine Ebewe” 4. Possible side effects 5 How to store Cytarabine Ebewe” 6. Contents of the pack and other information 1. WHAT CYTARABINE IS AND WHAT IT IS USED FOR Cytarabine “Ebewe” solution for injection or infusion, contains the active substance Cytarabine The drug Cytarabine is used to treat cancer. It can be used alone but more commonly it is used in combination with other anti-cancer agents. Cytarabine can be used as monotherapy or in combination with other chemotherapeutics in adults and children with some types of leukaemia (cancer affecting the blood): Acute myeloid leukaemia Acute non-lymphoblastic leukaemia Acute lymphocytic leukaemia Erythroleukaemia Blast crises of chronic myeloid leukaemia 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE CYTARABINE “EBEWE” DO NOT TAKE CYTARABINE ”EBEWE”: If you are hypersensitive (severe allergy) to cytarabine or any of the other ingredients of Cytarabine “Ebewe”. If your bone marrow is still recovering from damage caused by other medicines (your doctor will check for this using blood test and will Lue koko asiakirja
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Cytarabine Ebewe 50mg/ml solution for injection or infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1ml solution for injection or infusion contains 50 mg Cytarabine Each 10ml solution for injection or infusion contains 500 mg Cytarabine Each 20ml solution for injection or infusion contains 1000 mg Cytarabine Each 40ml solution for injection or infusion contains 2000 mg Cytarabine Excipients: This medicinal product contains 2.14mg of sodium in 1ml of solution. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection or infusion Clear, colourless sterile solution 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cytarabine can be used alone or in combination for induction of remission and/or maintenance therapy in patients with acute myeloid leukaemia, acute non-lymphoplastic leukaemias, erythroleukaemia, blast crises of chronic myeloid leukaemia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY Cytarabine “Ebewe” can be diluted with water for injection BP, Glucose intravenous infusion BP or sodium chloride intravenous infusion BP. METHOD OF ADMINISTRATION May be administered intravenously (IV) or subcutaneously (SC) only. The product is hypertonic and must not be administered by the intrathecal route. The following doses are given as a guide, but the clinician should consult relevant protocols for the appropriate dosage of cytarabine and other antineoplastic agents given in combination. Most doses are given in mg/kg but may be converted to doses related to surface area by the use of standard nomograms. Remission Induction (Adults): Continuous Dosing: The usual dose in leukaemia is 2 mg/kg by rapid intravenous injection daily for ten days. If after ten days neither ther Lue koko asiakirja